SCHEMBL22990767

SCHEMBL22990767

CN(C(=O)[C@@H](N)CO)c1ccc(F)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
TSHR P16473 3/20 0.38
KDM4E B2RXH2 1/20 0.38
SLC1A3 P43003 2/20 0.37
SLC1A2 P43004 2/20 0.37
SLC1A1 P43005 2/20 0.37
KMT2A Q03164 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.36
POLQ O75417 2/20 0.36
AAK1 Q2M2I8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28763851 1.00 ALDH1A1 (0.46) ALDH1A1TSHRKDM4ESLC1A3SLC1A2
SCHEMBL29177665 0.83 ALDH1A1 (0.42) ALDH1A1TSHRKDM4ESLC1A3SLC1A2
SCHEMBL28763892 0.81 ALDH1A1 (0.42) ALDH1A1TSHRKDM4EKMT2ANPC1
SCHEMBL28763890 0.81 ALDH1A1 (0.42) ALDH1A1TSHRKDM4EKMT2ANPC1
SCHEMBL22981289 0.80 ALDH1A1 (0.43) ALDH1A1TSHRKDM4EKMT2ANPC1
SCHEMBL22289684 0.79 MLYCD (0.39) KDM4EKMT2APOLQ
SCHEMBL22289683 0.79 MLYCD (0.39) KDM4EKMT2APOLQ
SCHEMBL29177690 0.78 EGFR (0.39) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL23537716 0.77 ALDH1A1 (0.50) ALDH1A1TSHRKMT2ANPC1RAB9A
SCHEMBL30638957 0.76 ALDH1A1 (0.51) ALDH1A1TSHRKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114667167-B Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-12-20 CN disclosed
EP-4010080-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-09-27 EP disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 US disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 US disclosed
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2022-09-22 US disclosed
CN-114667167-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2022-06-24 CN disclosed
EP-4010080-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2022-06-15 EP disclosed
WO-2021028643-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 ALDH1A1 97/4885TSHR 3400/4885KDM4E 1609/4885
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 ALDH1A1 97/4885TSHR 3400/4885KDM4E 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.